Moreover, the results of our study showed that cytotoxic drugs used in the induction treatment of ALL can influence CD19, CD20 and CD58 antigen expression on blast cells that can play an essential role in the treatment of resistant or relapsed disease or antigens that could potentially influence the future stratification of patients into risk groups important for planning the treatment. Here, CD19 is linked to acute lymphoblastic leukemia.